EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hexahydroquinoline Derivatives Are Selective Agonists for the Adhesion G Protein-Coupled Receptor ADGRG1/GPR56

Alexander L Vizurraga, Michael J Robertson, Maiya Yu, Georgios Skiniotis, Gregory G Tall iD

Molecular Pharmacology · 2023

DOI: 10.1124/molpharm.123.000688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmacology, 2023. Verfasst von Alexander L Vizurraga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Michigan School of Medicine, Ann Arbor, Michigan (A.L.V., M.Y., G.G.T.); and. Hauptthemen laut MEDLINE: Neoplasms, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NICHD NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GPR56 is a widely expressed adhesion GPCR (AGPCR) that has pleotropic roles in brain development, platelet function, cancer, and more. Nearly all AGPCRs possess extracellular regions that bind protein ligands and conceal a cryptic tethered peptide agonist. AGPCR reception of mechanical or shear force is thought to release the tethered agonist permitting its binding to the AGPCR orthosteric site for consequent activation of G protein signaling. This multistep mechanism of AGPCR activation is difficult to target, emphasizing the need for tool compounds and potential therapeutics that modulate AGPCRs directly. We expanded our cell-based pilot screen for GPR56 small molecule activators to screen >200,000 compounds and identified two promising agonists: 2-(furan-2-yl)-1-[(4-phenylphenyl)carbonyl]pyrrolidine, or compound 4, and propan-2-yl-4-(2-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, or compound 36. Both compounds activated GPR56 receptors enginered to have impaired tethered agonists and/or be cleavage deficient. Compound 4 activated a subset of group VIII AGPCRs while compound 36 had exclusive specificity for GPR56 among the GPCRs tested. Compound 36 SAR analysis identified an analog with the isopropyl R group replaced with a cyclopentyl ring and the electrophilic bromine replaced with a CF3 group. Analog 36.40 had 40% increased potency over compound 36 and was 20-fold more potent than synthetic peptidomimetics designed from the GPR56 tethered agonist. The new GPCR56 tool compounds discovered in this screen may be used to further advance understanding of GPR56 function and aid development of AGPCR-targeted therapeutics. SIGNIFICANCE STATEMENT: Adhesion G protein coupled receptors (AGPCRs) are a large, clinically relevant class of GPCRs with no available therapeutics, in part due to their unique mechanism of activation. GPR56 is a widely expressed model AGPCR involved in cancer metastasis, hemostasis, and neuron myelination. In the present study, we identified novel small molecule agonists for GPR56. These molecules are among the most potent identified thus far and may become useful leads in the development of a GPR56-targeted therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, G-Protein-CoupledHumansCell AdhesionPeptidesSignal Transduction

Substanzen

PeptidesReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Department of Pharmacology, University of Michigan School of Medicine, Ann Arbor, Michigan (A.L.V., M.Y., G.G.T.); and.
  • Departments of Molecular and Cellular Physiology (M.J.R., G.S.) and Structural Biology (G.S.), Stanford University School of Medicine, Stanford, California.
  • Department of Pharmacology, University of Michigan School of Medicine, Ann Arbor, Michigan (A.L.V., M.Y., G.G.T.); and gregtall@umich.edu.
  • Departments of Molecular and Cellular Physiology (M.J.R., G.S.) and Structural Biology (G.S.), Stanford University School of Medicine, Stanford, California gregtall@umich.edu.

ORCID-Profile: Gregory G Tall

Förderung

  • NHLBI NIH HHS
  • NICHD NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Vizurraga, A. L., Robertson, M. J., Yu, M., Skiniotis, G., & Tall, G. G. (2023). Hexahydroquinoline Derivatives Are Selective Agonists for the Adhesion G Protein-Coupled Receptor ADGRG1/GPR56. Molecular Pharmacology. https://doi.org/10.1124/molpharm.123.000688

Vancouver

Vizurraga AL, Robertson MJ, Yu M, Skiniotis G, Tall GG. Hexahydroquinoline Derivatives Are Selective Agonists for the Adhesion G Protein-Coupled Receptor ADGRG1/GPR56. Molecular Pharmacology. 2023. doi:10.1124/molpharm.123.000688

BibTeX
@article{Vizurraga2023,
  author = {Vizurraga, Alexander L and Robertson, Michael J and Yu, Maiya and Skiniotis, Georgios and Tall, Gregory G},
  title = {Hexahydroquinoline Derivatives Are Selective Agonists for the Adhesion G Protein-Coupled Receptor ADGRG1/GPR56},
  journal = {Molecular Pharmacology},
  year = {2023},
  doi = {10.1124/molpharm.123.000688}
}
Kostenlos starten →